The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

mRNA is like Hermes, delivering the genetic code to cellular construction sites, so it has long
been of interest, but only to a small group of scientists, and only demonstrating its …

Immune checkpoint blockade (ICB) therapy has recently shown promise in treating several
malignancies. However, only a limited number of patients respond to this treatment, partially …

Chimeric antigen receptor natural killer cells (CAR-NK) promote off-the-shelf cellular therapy
for solid tumors and malignancy. However,, the development of CAR-NK is due to their …

Pyroptosis is a form of proinflammatory cell death that depends on the gasdermin family of
proteins. The main features of pyroptosis are altered membrane permeability, cell swelling …

Many patients have achieved a favorable overall survival rate since allogenic hematopoietic
stem cell transplantation (allo-HSCT) has been widely implemented to treat hematologic …

Objective: The human cluster of differentiation (CD) 300A, a type-I transmembrane protein
with immunoreceptor tyrosine-based inhibitory motifs, was investigated as a potential …

Cellular therapies have revolutionized the treatment of hematological malignancies since
their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is …

Objective The aim of this study was to explore the safety and efficacy of multiple peptide-
pulsed autologous dendritic cells (DCs) combined with cytotoxic T lymphocytes (CTLs) in …

Objective: Immature vasculature lacking pericyte coverage substantially contributes to tumor
growth, drug resistance, and cancer cell dissemination. We previously demonstrated that …